Please Note: You are now leaving a Boehringer Ingelheim Pharmaceuticals, Inc. site. Boehringer Ingelheim Pharmaceuticals, Inc. has not reviewed the contents of all the pages and sites that may be linked to this site. Boehringer Ingelheim Pharmaceuticals, Inc. is not responsible for, and disclaims any liability to, the content of any other page or site or for any viruses or similar harmful programs that may be present on such pages or sites. Linking to any other page or site is at your own risk.
|
Aggrenox® (aspirin/extended-release dipyridamole) 25 mg/200 mg capsules should be avoided in patients allergic to any ingredient in AGGRENOX, allergic to non-steroidal anti-inflammatory drugs (NSAIDS), or who have the combination of asthma, runny nose and nasal polyps. AGGRENOX should not be given to a child or teenager due to the risk of Reye’s syndrome.
AGGRENOX may cause an increased bleeding risk, including into the brain, stomach or intestines and any bleeding may take longer to stop. AGGRENOX should be avoided in patients with a history of stomach ulcers or those who drink three or more alcoholic drinks a day due to the risk of bleeding. Patients should inform their doctor of all medications they are currently taking including NSAIDS or blood thinners.
AGGRENOX should be avoided during pregnancy, especially in the third trimester, or in patients with severe liver or kidney problems. The most common side effects of AGGRENOX are headache, upset stomach and diarrhea.
What is AGGRENOX?
AGGRENOX is a prescription medication used to lower the risk of stroke in people who have had a “mini-stroke” (transient ischemia attack or TIA) or stroke due to a blood clot.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information including Patient Information.
NEED HELP PAYING FOR AGGRENOX?
Our patient assistance program may be able to help. Call 1-800-556-8317 to find out more.
Privacy Policy | Terms of Use | Contact Us | Full Site
Content intended for U.S. residents only.
Copyright © 2012 - 2015 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.